The major factors determining pharmacologic drug responses are the input and disposition rates controlling pharmacokinetics, drug distribution to the site of action (biophase), the mechanism of drug action in altering mediator or receptor levels, and transduction processes which follow the latter. The Principal Investigator has developed a family of four indirect response (IDR) models to account for drug action on the mediators of the response rather than directly causing the response. Because these IDR models along with added complexities currently require analysis using differential equations which often cannot be fully integrated, the Principal Investigator proposes to use advanced methods for calculus and simulation to seek exact or approximate solutions or behaviors for such models in order to yield improved insights and methods for understanding the time course of drug response as related to major mechanisms of action. This project seeks to characterize and quantify the problem of drugs acting by direct and indirect mechanisms.
Specific aims i nclude: elucidating properties of IDR when drug is given by short and long-term infusions, identifying parameters determining the linear return rates of responses, using moment analysis to characterize experimental data, dealing with variable baseline behaviors, addition of a precursor compartment to account for tolerance and rebound effects, and applying irreversible rather than reversible inhibition of the response variable. Advanced methods of calculus and simulations will be employed to seek exact or approximate solutions or behaviors for these models, to identify how the onset, extent, return, duration, AUC, and mean times of responses are controlled, to recover parameters more easily from experimental data, and to discriminate among diverse models available to describe various, types of data. These efforts should yield improved insights and methods for understanding the time course of drug responses as related to major mechanisms of action.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
1R01GM057980-01
Application #
2677497
Study Section
Special Emphasis Panel (ZRG4-PTHA (01))
Project Start
1998-08-01
Project End
2001-07-31
Budget Start
1998-08-01
Budget End
1999-07-31
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
State University of New York at Buffalo
Department
Other Health Professions
Type
Schools of Pharmacy
DUNS #
038633251
City
Buffalo
State
NY
Country
United States
Zip Code
14260
Nguyen, Ly M; Singh, Aman P; Wiczling, Pawel et al. (2018) Dynamics of Erythropoietic Biomarkers in Response to Treatment With Erythropoietin in Belgrade Rats. Front Pharmacol 9:316
Ramakrishnan, Vidya; Mager, Donald E (2018) Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells. J Pharmacol Exp Ther 365:734-751
Nanavati, Charvi; Mager, Donald E (2017) Sequential Exposure of Bortezomib and Vorinostat is Synergistic in Multiple Myeloma Cells. Pharm Res 34:668-679
Miao, Xin; Koch, Gilbert; Straubinger, Robert M et al. (2016) Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells. Cancer Chemother Pharmacol 77:181-93
Nanavati, Charvi; Mager, Donald E (2016) Calculated Log D Is Inversely Correlated With Select Camptothecin Clearance and Efficacy in Colon Cancer Xenografts. J Pharm Sci 105:1561-6
Chudasama, Vaishali L; Ovacik, Meric A; Abernethy, Darrell R et al. (2015) Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells. J Pharmacol Exp Ther 354:448-58
Singh, Aman P; Krzyzanski, Wojciech; Martin, Steven W et al. (2015) Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition. AAPS J 17:389-99
Zhu, Xu; Straubinger, Robert M; Jusko, William J (2015) Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. J Pharmacokinet Pharmacodyn 42:477-96
Zhao, Jie; Cao, Yanguang; Jusko, William J (2015) Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model. Pharm Res 32:3269-81
McCune, Jeannine S; Vicini, Paolo; Salinger, David H et al. (2015) Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration. Cancer Chemother Pharmacol 75:67-75

Showing the most recent 10 out of 111 publications